<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38941608</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-3278</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annual review of immunology</Title><ISOAbbreviation>Annu Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19.</ArticleTitle><Pagination><StartPage>615</StartPage><EndPage>645</EndPage><MedlinePgn>615-645</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev-immunol-083122-043545</ELocationID><Abstract><AbstractText>The COVID-19 pandemic was caused by the recently emerged &#x3b2;-coronavirus SARS-CoV-2. SARS-CoV-2 has had a catastrophic impact, resulting in nearly 7 million fatalities worldwide to date. The innate immune system is the first line of defense against infections, including the detection and response to SARS-CoV-2. Here, we discuss the innate immune mechanisms that sense coronaviruses, with a focus on SARS-CoV-2 infection and how these protective responses can become detrimental in severe cases of COVID-19, contributing to cytokine storm, inflammation, long-COVID, and other complications. We also highlight the complex cross talk among cytokines and the cellular components of the innate immune system, which can aid in viral clearance but also contribute to inflammatory cell death, cytokine storm, and organ damage in severe COVID-19 pathogenesis. Furthermore, we discuss how SARS-CoV-2 evades key protective innate immune mechanisms to enhance its virulence and pathogenicity, as well as how innate immunity can be therapeutically targeted as part of the vaccination and treatment strategy. Overall, we highlight how a comprehensive understanding of innate immune mechanisms has been crucial in the fight against SARS-CoV-2 infections and the development of novel host-directed immunotherapeutic strategies for various diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malireddi</LastName><ForeName>R K Subbarao</ForeName><Initials>RKS</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: Thirumala-Devi.Kanneganti@StJude.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Bhesh Raj</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: Thirumala-Devi.Kanneganti@StJude.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanneganti</LastName><ForeName>Thirumala-Devi</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: Thirumala-Devi.Kanneganti@StJude.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 CA253095</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI101935</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI124346</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI101935</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI160179</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR056296</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Rev Immunol</MedlineTA><NlmUniqueID>8309206</NlmUniqueID><ISSNLinking>0732-0582</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PANoptosis</Keyword><Keyword MajorTopicYN="N">RIPK</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">caspase</Keyword><Keyword MajorTopicYN="N">cell death</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>16</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38941608</ArticleId><ArticleId IdType="mid">NIHMS2011785</ArticleId><ArticleId IdType="pmc">PMC11373870</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-083122-043545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kronvall G, Nordenfelt E. 2021. On the history of human coronaviruses. APMIS 129:381&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014751</ArticleId><ArticleId IdType="pubmed">33624304</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. 2020. Middle East respiratory syndrome. Lancet 395:1063&#x2013;77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155742</ArticleId><ArticleId IdType="pubmed">32145185</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TS, Liu DX. 2021. Similarities and dissimilarities of COVID-19 and other coronavirus diseases. Annu. Rev. Microbiol 75:19&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">33492978</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497&#x2013;506</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Zhao X, Ma X, Wang W, Niu P, et al. 2020. A novel coronavirus genome identified in a cluster of pneumonia cases &#x2013; Wuhan, China 2019&#x2013;2020. China CDC Wkly 2:61&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393069</ArticleId><ArticleId IdType="pubmed">34594763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D, Vanelli M. 2020. WHO declares COVID-19 a pandemic. Acta Biomed 91:157&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis 20:533&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, et al. 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med 26:1636&#x2013;43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Kanneganti T-D. 2021. The &#x2018;cytokine storm&#x2019;: molecular mechanisms and therapeutic prospects. Trends Immunol 42:681&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310545</ArticleId><ArticleId IdType="pubmed">34217595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai C, Zhong Q, Gao GF. 2022. Overview of SARS-CoV-2 genome-encoded proteins. Sci. China Life Sci 65:280&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362648</ArticleId><ArticleId IdType="pubmed">34387838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, et al. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, et al. 2020. A new coronavirus associated with human respiratory disease in China. Nature 579:265&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu J, Nie J, Zhang L, Hao H, et al. 2020. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182:1284&#x2013;94.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, Ye G, Geng Q, et al. 2020. Cell entry mechanisms of SARS-CoV-2. PNAS 117:11727&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Kanneganti T-D. 2022. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol 23:165&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Kanneganti T-D. 2022. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J. Transl. Med 20:542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682745</ArticleId><ArticleId IdType="pubmed">36419185</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring J, Perlman S. 2001. Mouse hepatitis virus. Curr. Opin. Microbiol 4:462&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129732</ArticleId><ArticleId IdType="pubmed">11495812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Channappanavar R, Kanneganti T-D. 2020. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol 41:1083&#x2013;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561287</ArticleId><ArticleId IdType="pubmed">33153908</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Lee S, Mall R, Pandian N, Wang Y, et al. 2022. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Sci. Immunol 7:eabo6294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161373</ArticleId><ArticleId IdType="pubmed">35587515</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, et al. 2021. Synergism of TNF-&#x3b1; and IFN-&#x3b3; triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184:149&#x2013;68.e17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat. Rev. Immunol 4:499&#x2013;511</Citation><ArticleIdList><ArticleId IdType="pubmed">15229469</ArticleId></ArticleIdList></Reference><Reference><Citation>Uematsu S, Akira S. 2007. Toll-like receptor and innate immunity. Seikagaku 79:769&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">17877023</ArticleId></ArticleIdList></Reference><Reference><Citation>Plan&#xe8;s R, Bert JB, Tairi S, BenMohamed L, Bahraoui E. 2022. SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: a novel molecular target for COVID-19 interventions. Viruses 14:999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146335</ArticleId><ArticleId IdType="pubmed">35632741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung PS, Yang SP, Peng YC, Sun CP, Tao MH, Hsieh SL. 2022. CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. J. Biomed. Sci 29:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277873</ArticleId><ArticleId IdType="pubmed">35820906</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W, Ju J, Gu M, Wang X, Liu S, et al. 2023. SARS-CoV-2 envelope protein triggers depression-like behaviors and dysosmia via TLR2-mediated neuroinflammation in mice. J. Neuroinflamm 20:110</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10166055</ArticleId><ArticleId IdType="pubmed">37158916</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. 2021. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. eLife 10:e68563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, et al. 2021. SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Res 31:818&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Petruk G, Puthia M, Petrlova J, Samsudin F, Stromdahl AC, et al. 2020. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. J. Mol. Cell Biol 12:916&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799037</ArticleId><ArticleId IdType="pubmed">33295606</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontes-Dantas FL, Fernandes GG, Gutman EG, De Lima EV, Antonio LS, et al. 2023. SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep 42:112189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9935273</ArticleId><ArticleId IdType="pubmed">36857178</ArticleId></ArticleIdList></Reference><Reference><Citation>Totura AL, Whitmore A, Agnihothram S, Schafer A, Katze MG, et al. 2015. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio 6:e00638&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447251</ArticleId><ArticleId IdType="pubmed">26015500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamir H, Melamed S, Erez N, Politi B, Yahalom-Ronen Y, et al. 2022. Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection. Viruses 14:189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878863</ArticleId><ArticleId IdType="pubmed">35215785</ArticleId></ArticleIdList></Reference><Reference><Citation>Menezes MCS, Veiga ADM, Martins de Lima T, Kunimi Kubo Ariga S, Vieira Barbeiro H, et al. 2021. Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients. Sci. Rep 11:15223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316546</ArticleId><ArticleId IdType="pubmed">34315957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, et al. 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas D, Bogamuwa S, Piper B, Newcomb G, Gunturu P, et al. 2023. A role for Toll-like receptor 3 in lung vascular remodeling associated with SARS-CoV-2 infection. bioRxiv 2023.01.25.524586. 10.1101/2023.01.25.524586</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.25.524586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, et al. 2021. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms 9:1820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465566</ArticleId><ArticleId IdType="pubmed">34576716</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sluis RM, Cham LB, Gris-Oliver A, Gammelgaard KR, Pedersen JG, et al. 2022. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J 41:e109622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108609</ArticleId><ArticleId IdType="pubmed">35178710</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Eutimio MA, Lopez-Macias C, Pastelin-Palacios R. 2020. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect 22:226&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192074</ArticleId><ArticleId IdType="pubmed">32361001</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezcua-Guerra LM, Rojas-Velasco G, Brianza-Padilla M, V&#xe1;zquez-Rangel A, M&#xe1;rquez-Velasco R, et al. 2021. Presence of antiphospholipid antibodies in COVID-19: a case series study. Ann. Rheum. Dis 80:e73.</Citation><ArticleIdList><ArticleId IdType="pubmed">32753426</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, et al. 2022. Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J. Clin. Immunol 42:471&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798309</ArticleId><ArticleId IdType="pubmed">35091979</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, et al. 2021. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol 6:eabl4348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell TM, Liu Z, Zhang Q, Moncada-Velez M, Covill LE, et al. 2022. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. J. Exp. Med 219:e20220202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178406</ArticleId><ArticleId IdType="pubmed">35670811</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A. 2022. A case of autosomal recessive interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J. Clin. Immunol 42:19&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553400</ArticleId><ArticleId IdType="pubmed">34713375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, et al. 2022. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J. Exp. Med 219:e20220131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo YM, Gale M Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177755</ArticleId><ArticleId IdType="pubmed">21616437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel J, Gack MU. 2020. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol 20:537&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094958</ArticleId><ArticleId IdType="pubmed">32203325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, et al. 2021. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 34:108628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832566</ArticleId><ArticleId IdType="pubmed">33440148</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Geng T, Harrison AG, Wang P. 2021. Differential roles of RIG-I-like receptors in SARS-CoV-2 infection. Mil. Med. Res 8:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8421188</ArticleId><ArticleId IdType="pubmed">34488908</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne LG, Reuschl AK, Zuliani-Alvarez L, Whelan MVX, Turner J, et al. 2021. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J 40:e107826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209947</ArticleId><ArticleId IdType="pubmed">34101213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouwaki T, Nishimura T, Wang G, Oshiumi H. 2021. RIG-I-like receptor-mediated recognition of viral genomic RNA of severe acute respiratory syndrome coronavirus-2 and viral escape from the host innate immune responses. Front. Immunol 12:700926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267574</ArticleId><ArticleId IdType="pubmed">34249006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, et al. 2021. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol 22:820&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">33976430</ArticleId></ArticleIdList></Reference><Reference><Citation>Loske J, Rohmel J, Lukassen S, Stricker S, Magalhaes VG, et al. 2022. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat. Biotechnol 40:319&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">34408314</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill LAJ, Netea MG. 2020. BCG-induced trained immunity: Can it offer protection against COVID-19? Nat. Rev. Immunol 20:335&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212510</ArticleId><ArticleId IdType="pubmed">32393823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma BR, Kanneganti T-D. 2021. NLRP3 inflammasome in cancer and metabolic diseases. Nat. Immunol 22:550&#x2013;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132572</ArticleId><ArticleId IdType="pubmed">33707781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P, Shen M, Yu Z, Ge W, Chen K, et al. 2021. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat. Commun 12:4664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329225</ArticleId><ArticleId IdType="pubmed">34341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Eltobgy MM, Zani A, Kenney AD, Estfanous S, Kim E, et al. 2022. Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis. PNAS 119:e2202012119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173818</ArticleId><ArticleId IdType="pubmed">35588457</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TS, de S&#xe1; KSG, Ishimoto AY, Becerra A, Oliveira S, et al. 2021. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med 218:e20201707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AC, Soares VC, de Azevedo-Quintanilha IG, Dias S, Fintelman-Rodrigues N, et al. 2021. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discov 7:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919254</ArticleId><ArticleId IdType="pubmed">33649297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Williams EP, Malireddi RKS, Karki R, Banoth B, et al. 2020. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. J. Biol. Chem 295:14040&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7549031</ArticleId><ArticleId IdType="pubmed">32763970</ArticleId></ArticleIdList></Reference><Reference><Citation>Plan&#xe8;s R, Pinilla M, Santoni K, Hessel A, Passemar C, et al. 2022. Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. Mol. Cell 82:2385&#x2013;400.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108100</ArticleId><ArticleId IdType="pubmed">35594856</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo A, Ranjbar S, de Lacerda LB, Lewandrowski M, et al. 2022. Fc&#x3b3;R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 606:576&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Xie X, Feng XL, Xu L, Han JB, et al. 2022. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. EBioMedicine 75:103803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719059</ArticleId><ArticleId IdType="pubmed">34979342</ArticleId></ArticleIdList></Reference><Reference><Citation>Albornoz EA, Amarilla AA, Modhiran N, Parker S, Li XX, et al. 2022. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol. Psychiatry 28:2878&#x2013;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10615762</ArticleId><ArticleId IdType="pubmed">36316366</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpinar S, Oran M, Dogan M, Celikkol A, Erdem I, Turgut B. 2021. The role of oxidized phospholipids in COVID-19-associated hypercoagulopathy. Eur. Rev. Med. Pharmacol. Sci 25:5304&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">34486706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn M, Chen VC, Rozario P, Ng WL, Kong PS, et al. 2023. Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases. Cell 186:2144&#x2013;59.e22</Citation><ArticleIdList><ArticleId IdType="pubmed">37172565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhang Y, Wang R, Liu X, Zhao J, et al. 2022. SARS-CoV-2 infection of intestinal epithelia cells sensed by RIG-I and DHX-15 evokes innate immune response and immune cross-talk. Front. Cell. Infect. Microbiol 12:1035711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9941539</ArticleId><ArticleId IdType="pubmed">36825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YM, Zheng Y, Yu Y, Wang Y, Huang Q, et al. 2020. Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. EMBO J 39:e105896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737620</ArticleId><ArticleId IdType="pubmed">33140861</ArticleId></ArticleIdList></Reference><Reference><Citation>Decout A, Katz JD, Venkatraman S, Ablasser A. 2021. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol 21:548&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029610</ArticleId><ArticleId IdType="pubmed">33833439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Zhang X, Lei X, Xiao X, Jiao T, et al. 2021. Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection. Signal Transduct. Target Ther 6:382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564796</ArticleId><ArticleId IdType="pubmed">34732709</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wei L, Xu F, Zhao F, Huang Y, et al. 2022. SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response. Sci. Signal 15:eabg8744.</Citation><ArticleIdList><ArticleId IdType="pubmed">35412852</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries F, Shmuel-Galia L, Jiang Z, Wilson R, Landis P, et al. 2021. A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection. Sci. Immunol 6:eabi9002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158975</ArticleId><ArticleId IdType="pubmed">34010139</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Ferretti M, Ying B, Descamps H, Lee E, et al. 2021. Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci. Immunol 6:eabi9007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10021026</ArticleId><ArticleId IdType="pubmed">34010142</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, et al. 2014. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med 371:507&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174543</ArticleId><ArticleId IdType="pubmed">25029335</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, et al. 2022. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 603:145&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891013</ArticleId><ArticleId IdType="pubmed">35045565</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeldt CJ, Cerikan B, Cortese M, Frankish J, Lee JY, et al. 2022. SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-&#x3ba;B. Commun. Biol 5:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755718</ArticleId><ArticleId IdType="pubmed">35022513</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GD, Willment JA, Whitehead L. 2018. C-type lectins in immunity and homeostasis. Nat. Rev. Immunol 18:374&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">29581532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, Liu J, Zhao S, Gomez Castro MF, Laurent-Rolle M, et al. 2021. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity 54:1304&#x2013;19.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8106883</ArticleId><ArticleId IdType="pubmed">34048708</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz DH, Tahir UA, Ngo D, Benson MD, Bick AG, et al. 2020. Proteomic profiling in biracial cohorts implicates DC-SIGN as a mediator of genetic risk in COVID-19. medRxiv 2020.06.09.20125690. 10.1101/2020.06.09.20125690</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.09.20125690</ArticleId></ArticleIdList></Reference><Reference><Citation>Thepaut M, Luczkowiak J, Vives C, Labiod N, Bally I, et al. 2021. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. PLOS Pathog 17:e1009576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136665</ArticleId><ArticleId IdType="pubmed">34015061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lempp FA, Soriaga LB, Montiel-Ruiz M, Benigni F, Noack J, et al. 2021. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598:342&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">34464958</ArticleId></ArticleIdList></Reference><Reference><Citation>Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, et al. 2021. Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic. J. Infect. Dis 223:981&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799006</ArticleId><ArticleId IdType="pubmed">33367731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigerblad G, Warner SA, Ramos-Benitez MJ, Kardava L, Tian X, et al. 2023. Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. Sci. Adv 9:eade8272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812373</ArticleId><ArticleId IdType="pubmed">36598976</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, Perera R, Scott M, et al. 2020. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369:1210&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang T, Yang J, Deng H, Chen D, Yang X, Tang ZH. 2022. Depletion and dysfunction of dendritic cells: understanding SARS-CoV-2 infection. Front. Immunol 13:843342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898834</ArticleId><ArticleId IdType="pubmed">35265087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Wherry EJ. 2020. T cell responses in patients with COVID-19. Nat. Rev. Immunol 20:529&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7389156</ArticleId><ArticleId IdType="pubmed">32728222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184:861&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, et al. 2020. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369:eabc8511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, et al. 2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med 26:1070&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourda M, Dzidic M, Hertwig L, Bergsten H, Palma Medina LM, et al. 2021. High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. PNAS 118:e2109123118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501786</ArticleId><ArticleId IdType="pubmed">34548411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, et al. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, et al. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms JC, Biermann J, Huang H, Wang Y, Nair A, et al. 2021. A molecular single-cell lung atlas of lethal COVID-19. Nature 595:114&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, et al. 2023. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature 617:764&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10208981</ArticleId><ArticleId IdType="pubmed">37198478</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Liu Y, Yuan J, Wen Y, Xu G, et al. 2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med 26:842&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauters E, Van Mol P, Garg AD, Jansen S, Van Herck Y, et al. 2021. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res 31:272&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027624</ArticleId><ArticleId IdType="pubmed">33473155</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalskov L, Mohlenberg M, Thyrsted J, Blay-Cadanet J, Poulsen ET, et al. 2020. SARS-CoV-2 evades immune detection in alveolar macrophages. EMBO Rep 21:e51252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645910</ArticleId><ArticleId IdType="pubmed">33112036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Wen W, Fan X, Hou W, Su B, et al. 2021. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184:1895&#x2013;913.e19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857060</ArticleId><ArticleId IdType="pubmed">33657410</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Mears JR, Shakib L, Beynor JI, Shanaj S, et al. 2021. IFN-&#x3b3; and TNF-&#x3b1; drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med 13:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057009</ArticleId><ArticleId IdType="pubmed">33879239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, et al. 2020. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182:1419&#x2013;40.e23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, et al. 2020. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27:992&#x2013;1000.e3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, et al. 2020. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182:1401&#x2013;18.e18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405878</ArticleId><ArticleId IdType="pubmed">32810439</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinetti T, Hirzel C, Fux M, Walti LN, Schober P, et al. 2020. Reduced monocytic human leukocyte antigen-DR expression indicates immunosuppression in critically ill COVID-19 patients. Anesth. Analg 131:993&#x2013;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7288784</ArticleId><ArticleId IdType="pubmed">32925314</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson C, Kirsebom FCM. 2021. Neutrophils in respiratory viral infections. Mucosal Immunol 14:815&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985581</ArticleId><ArticleId IdType="pubmed">33758367</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges L, Pithon-Curi TC, Curi R, Hatanaka E. 2020. COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps. Mediat. Inflamm 2020:8829674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732408</ArticleId><ArticleId IdType="pubmed">33343232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri L, Hardin CC. 2020. Covid-19, angiogenesis, and ARDS endotypes. N. Engl. J. Med 383:182&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pubmed">32437597</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu Y, Xiang P, Pu L, Xiong H, et al. 2020. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J. Transl. Med 18:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237880</ArticleId><ArticleId IdType="pubmed">32434518</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, et al. 2020. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med 217:e20201129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, et al. 2020. Neutrophil extracellular traps in COVID-19. JCI Insight 5:e138999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, Campbell RA, Ng D, et al. 2020. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136:1169&#x2013;79</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Rosin NL, Arora R, Labit E, Jaffer A, et al. 2022. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat. Med 28:201&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaroli C, Fram T, Sharma NS, Patel SB, Tipper J, et al. 2023. Interferon-dependent signaling is critical for viral clearance in airway neutrophils. JCI Insight 8:e167042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10322684</ArticleId><ArticleId IdType="pubmed">37071484</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, et al. 2021. Basophils and mast cells in COVID-19 pathogenesis. Cells 10:2754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534912</ArticleId><ArticleId IdType="pubmed">34685733</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Torres AS, Salinas-Carmona MC, Salinas E, Rosas-Taraco AG. 2019. Eosinophils and respiratory viruses. Viral Immunol 32:198&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">31140942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DM, Kim Y, Seo JW, Lee J, Park U, et al. 2021. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell Rep 37:109798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450316</ArticleId><ArticleId IdType="pubmed">34587481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzaniga M, Fumagalli LAM, D&#x2019;Angelo L, Cerino M, Bonfanti G, et al. 2021. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int. J. Clin. Pract 75:e14047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995195</ArticleId><ArticleId IdType="pubmed">33497517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez L, Pekkarinen PT, Lakshmikanth T, Tan Z, Consiglio CR, et al. 2020. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Rep. Med 1:100078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405891</ArticleId><ArticleId IdType="pubmed">32838342</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone C, Dauphin A, et al. 2022. Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. eLife 11:e74681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038195</ArticleId><ArticleId IdType="pubmed">35275061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Kim H, Kim M, Yoon S, Lee S. 2023. Role of lymphoid lineage cells aberrantly expressing alarmins S100A8/A9 in determining the severity of COVID-19. Genes Genom 45:337&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9476394</ArticleId><ArticleId IdType="pubmed">36107397</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Salazar C, Sun JC. 2020. Natural killer cell responses to emerging viruses of zoonotic origin. Curr. Opin. Virol 44:97&#x2013;111</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7415341</ArticleId><ArticleId IdType="pubmed">32784125</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze JL, Aschenbrenner AC. 2021. COVID-19 and the human innate immune system. Cell 184:1671&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Malireddi RK, Kanneganti T-D. 2013. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Front. Cell. Infect. Microbiol 3:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824101</ArticleId><ArticleId IdType="pubmed">24273750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestka S, Krause CD, Walter MR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev 202:8&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">15546383</ArticleId></ArticleIdList></Reference><Reference><Citation>Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, et al. 2020. Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2. mBio 11:e01928&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484541</ArticleId><ArticleId IdType="pubmed">32913009</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, et al. 2020. Inhibition of SARS-CoV-2 by type I and type III interferons. J. Biol. Chem 295:13958&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7549028</ArticleId><ArticleId IdType="pubmed">32587093</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, et al. 2020. Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J. Virol 94:e00985&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7495371</ArticleId><ArticleId IdType="pubmed">32699094</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanifer ML, Kee C, Cortese M, Zumaran CM, Triana S, et al. 2020. Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. Cell Rep 32:107863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303637</ArticleId><ArticleId IdType="pubmed">32610043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulluev M, Yucel A, Kahraman ME, Bor MA. 2021. Measurement of some serum cytokines in nasal polyp and evaluation of its correlation with disease severity. Eur. Arch. Otorhinolaryngol 278:3345&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pubmed">33452622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Dong X, Ma R, Wang W, Xiao X, et al. 2020. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun 11:3810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. 2021. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol 6:eabl4340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Orlova E, Sozaeva L, Levy R, James A, et al. 2021. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med 218:e20210554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, et al. 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz-Zumaran C, Kee C, Doldan P, Guo C, Stanifer ML, Boulant S. 2022. Increased sensitivity of SARS-CoV-2 to type III interferon in human intestinal epithelial cells. J. Virol 96:e0170521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006957</ArticleId><ArticleId IdType="pubmed">35262371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn SY, Hearing J, Mugavero J, Kirillov V, Gorbunova E, et al. 2021. Interferon-lambda intranasal protection and differential sex pathology in a murine model of SARS-CoV-2 infection. mBio 12:e0275621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8561397</ArticleId><ArticleId IdType="pubmed">34724828</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, et al. 2020. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036&#x2013;45.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani IE, Rovina N, Lampropoulou V, Triantafyllia V, Manioudaki M, et al. 2021. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol 22:32&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, et al. 2020. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584:463&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G, Effort CHG, Meyts I. 2023. Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children. J. Allergy Clin. Immunol 151:832&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9951110</ArticleId><ArticleId IdType="pubmed">36841740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, et al. 2020. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369:718&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou J, Platt CD, Habiballah S, Nguyen AA, Elkins M, et al. 2021. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J. Allergy Clin. Immunol 148:732&#x2013;8.e1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252701</ArticleId><ArticleId IdType="pubmed">34224783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Le Pen J, Yatim A, Dong B, Aquino Y, et al. 2023. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. Science 379:eabo3627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10451000</ArticleId><ArticleId IdType="pubmed">36538032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PY, Platt CD, Weeks S, Grace RF, Maher G, et al. 2020. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J. Allergy Clin. Immunol 146:1194&#x2013;200.e1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445138</ArticleId><ArticleId IdType="pubmed">32853638</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. 2023. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol 21:133&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, et al. 2020. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med 26(10):1623&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wu H, Yao X, Zhang D, Zhou Y, et al. 2021. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell. Mol. Immunol 18:1305&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976727</ArticleId><ArticleId IdType="pubmed">33742186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Wang Y, Li K, Meyerholz DK, Allamargot C, Perlman S. 2021. Severe acute respiratory syndrome coronavirus 2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. J. Infect. Dis 223:785&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799009</ArticleId><ArticleId IdType="pubmed">33277988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, et al. 2022. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606:585&#x2013;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson DS, Pang J, Weir A, Kong IY, Fritsch M, et al. 2022. Interferon-&#x3b3; primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway. Immunity 55:423&#x2013;41.e9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822620</ArticleId><ArticleId IdType="pubmed">35139355</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R, Sundaram B, Sharma BR, Lee S, Malireddi RKS, et al. 2021. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell Rep 37:109858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853634</ArticleId><ArticleId IdType="pubmed">34686350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Karki R, Wang Y, Nguyen LN, Kalathur RC, Kanneganti T-D. 2021. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature 597:415&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8603942</ArticleId><ArticleId IdType="pubmed">34471287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose T, Man SM, Malireddi RK, Karki R, Kesavardhana S, et al. 2016. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci. Immunol 1:aag2045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131924</ArticleId><ArticleId IdType="pubmed">27917412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesavardhana S, Malireddi RKS, Burton AR, Porter SN, Vogel P, et al. 2020. The Z&#x3b1;2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development. J. Biol. Chem 295:8325&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294087</ArticleId><ArticleId IdType="pubmed">32350114</ArticleId></ArticleIdList></Reference><Reference><Citation>Banoth B, Tuladhar S, Karki R, Sharma BR, Briard B, et al. 2020. ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J. Biol. Chem 295:18276&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7939383</ArticleId><ArticleId IdType="pubmed">33109609</ArticleId></ArticleIdList></Reference><Reference><Citation>Christgen S, Zheng M, Kesavardhana S, Karki R, Malireddi RKS, et al. 2020. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). Front. Cell. Infect. Microbiol 10:237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274033</ArticleId><ArticleId IdType="pubmed">32547960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurung P, Burton A, Kanneganti T-D. 2016. NLRP3 inflammasome plays a redundant role with caspase 8 to promote IL-1&#x3b2;&#x2013;mediated osteomyelitis. 113:4452&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4843439</ArticleId><ArticleId IdType="pubmed">27071119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Vogel P, Kanneganti T-D. 2020. Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell 181:674&#x2013;87.e13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425208</ArticleId><ArticleId IdType="pubmed">32298652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram B, Pandian N, Mall R, Wang Y, Sarkar R, et al. 2023. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell 186:2783&#x2013;801.e20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10330523</ArticleId><ArticleId IdType="pubmed">37267949</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Zhang Y, Guan Z, Ye M, Li H, et al. 2023. SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses. Cell Res 33:201&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844202</ArticleId><ArticleId IdType="pubmed">36650286</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley AH. 2020. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat. Rev. Immunol 20:453&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296515</ArticleId><ArticleId IdType="pubmed">32546853</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. 2021. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 8:e524&#x2013;e33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078884</ArticleId><ArticleId IdType="pubmed">33930350</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. 2021. Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms. Scand. J. Immunol 93:e12967.</Citation><ArticleIdList><ArticleId IdType="pubmed">32875598</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis 71:762&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Wang Q, Zhang D, Ding J, Huang Q, et al. 2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target Ther 5:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100419</ArticleId><ArticleId IdType="pubmed">32296069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, et al. 2020. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell 183:143&#x2013;57.e13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. 2020. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol. Lett 225:31&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305732</ArticleId><ArticleId IdType="pubmed">32569607</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, et al. 2020. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med 26:1623&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke JM, Clair LA, Perera R, Parker R. 2021. SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block. RNA 27:1318&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522697</ArticleId><ArticleId IdType="pubmed">34315815</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Miorin L, Makio T, Dehghan I, Gao S, et al. 2021. Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci. Adv 7:eabe7386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7864571</ArticleId><ArticleId IdType="pubmed">33547084</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee AK, Blanco MR, Bruce EA, Honson DD, Chen LM, et al. 2020. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183:1325&#x2013;39.e21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543886</ArticleId><ArticleId IdType="pubmed">33080218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapointe CP, Grosely R, Johnson AG, Wang J, Fern&#xe1;ndez IS, Puglisi JD. 2021. Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation. PNAS 118:e2017715118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017934</ArticleId><ArticleId IdType="pubmed">33479166</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, et al. 2020. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 369:1249&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402621</ArticleId><ArticleId IdType="pubmed">32680882</ArticleId></ArticleIdList></Reference><Reference><Citation>Tidu A, Janvier A, Schaeffer L, Sosnowski P, Kuhn L, et al. 2020. The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation. RNA 27:253&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901841</ArticleId><ArticleId IdType="pubmed">33268501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Peng L, Park JJ, Hu Y, Devarkar SC, et al. 2020. Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. Mol. Cell 80:1055&#x2013;66.e6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833686</ArticleId><ArticleId IdType="pubmed">33188728</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Lee JH, Parker ZM, Acharya D, Chiang JJ, et al. 2021. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat. Microbiol 6:467&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103894</ArticleId><ArticleId IdType="pubmed">33727702</ArticleId></ArticleIdList></Reference><Reference><Citation>Munnur D, Teo Q, Eggermont D, Lee HHY, Thery F, et al. 2021. Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection. Nat. Immunol 22:1416&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">34663977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Xiao F, Hu D, Ge W, Tian M, et al. 2020. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-&#x3b2; production. Viruses 13:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823417</ArticleId><ArticleId IdType="pubmed">33396605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui L, Zhao Y, Wang W, Wu P, Wang Z, et al. 2021. SARS-CoV-2 membrane protein inhibits type I interferon production through ubiquitin-mediated degradation of TBK1. Front. Immunol 12:662989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168463</ArticleId><ArticleId IdType="pubmed">34084167</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso IP, Sanches K, Da Poian AT, Pinheiro AS, Almeida FCL. 2021. Dynamics of the SARS-CoV-2 nucleoprotein N-terminal domain triggers RNA duplex destabilization. Biophys. J 120:2814&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239202</ArticleId><ArticleId IdType="pubmed">34197802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubuk J, Alston JJ, Incicco JJ, Singh S, Stuchell-Brereton MD, et al. 2021. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun 12:1936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007728</ArticleId><ArticleId IdType="pubmed">33782395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Ye Q, Singh D, Cao Y, Diedrich JK, et al. 2021. The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. Nat. Commun 12:502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820290</ArticleId><ArticleId IdType="pubmed">33479198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Dai T, Qin Z, Pan T, Chu F, et al. 2021. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat. Cell Biol 23:718&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">34239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. 2021. SARS-CoV-2 N protein targets TRIM25-mediated RIG-I activation to suppress innate immunity. Viruses 13:1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402637</ArticleId><ArticleId IdType="pubmed">34452305</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L, Zhuang MW, Deng J, Zheng Y, Zhang J, et al. 2021. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. J. Med. Virol 93:5376&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242602</ArticleId><ArticleId IdType="pubmed">33913550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Shi Y, Pan X, Wu S, Hou R, et al. 2021. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep 34:108761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857071</ArticleId><ArticleId IdType="pubmed">33567255</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Liao CH, Wang Q, Tan YJ, Luo R, et al. 2020. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res 286:198074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309931</ArticleId><ArticleId IdType="pubmed">32589897</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, et al. 2020. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep 32:108185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473339</ArticleId><ArticleId IdType="pubmed">32941788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, et al. 2020. An mRNA vaccine against SARS-CoV-2 &#x2013; preliminary report. N. Engl. J. Med 383:1920&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, et al. 2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592:283&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, et al. 2020. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med 383:2439&#x2013;50</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, et al. 2021. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med 384:2187&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, et al. 2022. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med 386:531&#x2013;43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693692</ArticleId><ArticleId IdType="pubmed">34910859</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, et al. 2021. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med 385:1172&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Bijker EM. 2021. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol 21:83&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Karik&#xf3; K, T&#xfc;reci O. 2014. mRNA-based therapeutics &#x2013; developing a new class of drugs. Nat. Rev. Drug Discov 13:759&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pubmed">25233993</ArticleId></ArticleIdList></Reference><Reference><Citation>Karik&#xf3; K, Buckstein M, Ni H, Weissman D. 2005. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165&#x2013;75</Citation><ArticleIdList><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. 2015. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217:337&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pubmed">26342664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KQ, Burgute BD, Tzeng SC, Jing C, Jungers C, et al. 2022. N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. Cell Rep 40:111300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376333</ArticleId><ArticleId IdType="pubmed">35988540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nance KD, Meier JL. 2021. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci 7:748&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043204</ArticleId><ArticleId IdType="pubmed">34075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Chiew CJ, Lee VJ, Ong B, Lye DC, Tan KB. 2022. Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore. Lancet Reg. Health West. Pac 29:100654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716291</ArticleId><ArticleId IdType="pubmed">36471699</ArticleId></ArticleIdList></Reference><Reference><Citation>Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, et al. 2022. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. Clin. Infect. Dis 75:1442&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047219</ArticleId><ArticleId IdType="pubmed">35412612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, et al. 2022. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 27:301&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934254</ArticleId><ArticleId IdType="pubmed">34820940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. 2021. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 398:2173&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584828</ArticleId><ArticleId IdType="pubmed">34774196</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, et al. 2021. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 326:35&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, et al. 2022. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med 386:1397&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, et al. 2023. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis 76:e342&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC, Horby P, Lim WS, Emberson JR, Mafham M, et al. 2021. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med 384:693&#x2013;704</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne F, Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, et al. 2020. A living WHO guideline on drugs for covid-19. BMJ 370:m3379.</Citation><ArticleIdList><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, et al. 2021. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect. Dis 21:337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8035859</ArticleId><ArticleId IdType="pubmed">33838657</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed MAM, Mohamed AH, Owaynat AH. 2022. Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients. Egypt. J. Intern. Med 34:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853130</ArticleId><ArticleId IdType="pubmed">35194371</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton F, Confalonieri P, Centanni S, Mondoni M, Petrosillo N, et al. 2023. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur. Respir. J 61:2201514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9650195</ArticleId><ArticleId IdType="pubmed">36356972</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Perlman S. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol 39:529&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, et al. 2020. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig 130:2620&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. 2020. Cytokine release syndrome in severe COVID-19. Science 368:473&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, et al. 2022. A guide to immunotherapy for COVID-19. Nat. Med 28:39&#x2013;50</Citation><ArticleIdList><ArticleId IdType="pubmed">35064248</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, et al. 2018. Chimeric antigen receptor T-cell therapy &#x2013; assessment and management of toxicities. Nat. Rev. Clin. Oncol 15:47&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733403</ArticleId><ArticleId IdType="pubmed">28925994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, et al. 2021. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med 27:1752&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, et al. 2021. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10:e66125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034977</ArticleId><ArticleId IdType="pubmed">33682678</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinosoglou K, Kotsaki A, Gounaridi IM, Christaki E, Metallidis S, et al. 2023. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. EClinicalMedicine 56:101785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9791950</ArticleId><ArticleId IdType="pubmed">36590789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, Alvarez-Troncoso J, Gonzalez A, et al. 2023. Efficacy and safety of anakinra plus standard of care for patients with severe COVID-19: a randomized phase 2/3 clinical trial. JAMA Netw. Open 6:e237243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10082404</ArticleId><ArticleId IdType="pubmed">37027155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, et al. 2021. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med 384:795&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collab. Group. 2022. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400:359&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, et al. 2022. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med 10:1137&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451499</ArticleId><ArticleId IdType="pubmed">36087611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhan Y, Zhu L, Hou Z, Liu F, et al. 2020. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe 28:455&#x2013;64.e2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368656</ArticleId><ArticleId IdType="pubmed">32707096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, et al. 2020. Interferon-&#x3b1;2b treatment for COVID-19. Front. Immunol 11:1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242746</ArticleId><ArticleId IdType="pubmed">32574262</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, et al. 2021. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med 9:196&#x2013;206</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836724</ArticleId><ArticleId IdType="pubmed">33189161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoagland DA, M&#xf8;ller R, Uhl SA, Oishi K, Frere J, et al. 2021. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity 54:557&#x2013;70.e5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846242</ArticleId><ArticleId IdType="pubmed">33577760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A, Yao R, Lysvand H, Grodeland G, Legrand N, et al. 2021. Nafamostat&#x2013;interferon-&#x3b1; combination suppresses SARS-CoV-2 infection in vitro and in vivo by cooperatively targeting host TMPRSS2. Viruses 13:1768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473362</ArticleId><ArticleId IdType="pubmed">34578348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, et al. 2021. Synergistic interferon-alpha-based combinations for treatment of SARS-CoV-2 and other viral infections. Viruses 13:2489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8705725</ArticleId><ArticleId IdType="pubmed">34960758</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhani AA, Enani MA, Sharif-Askari FS, Alghareeb MR, Bin-Brikan RT, et al. 2021. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: a cohort study. PLOS ONE 16:e0252984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8191942</ArticleId><ArticleId IdType="pubmed">34111191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, Lung KC, Tso EY, Liu R, Chung TW, et al. 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395:1695&#x2013;704</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D, Stack R, Rothenburger T, Kandler JD, Ciesek S, et al. 2022. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants. J. Infect 85:573&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339084</ArticleId><ArticleId IdType="pubmed">35917841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhlband A, Fakhari A, Azizi H. 2021. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch. Pharmacol 394:829&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883756</ArticleId><ArticleId IdType="pubmed">33587164</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, et al. 2021. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, et al. 2022. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol 23:210&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, et al. 2020. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:1265&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. 2022. Long-term cardiovascular outcomes of COVID-19. Nat. Med 28:583&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Castaneda A, Lu P, Geraghty AC, Song E, Lee MH, et al. 2022. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 185:2452&#x2013;68.e16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, et al. 2022. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci. Transl. Med 14:eabq3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkai I, Mayer MG, Hellmers LM, Ning B, Huang Z, et al. 2022. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun 13:1745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975902</ArticleId><ArticleId IdType="pubmed">35365631</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. 2021. Mast cell activation symptoms are prevalent in long-COVID. Int. J. Infect. Dis 112:217&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Res. Initiat. 2022. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 400:452&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, et al. 2021. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol 22:829&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Schifanella L, Anderson J, Wieking G, Southern PJ, Antinori S, et al. 2023. The defenders of the alveolus succumb in COVID-19 pneumonia to SARS-CoV-2 and necroptosis, pyroptosis, and PANoptosis. J. Infect. Dis 227:1245&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226656</ArticleId><ArticleId IdType="pubmed">36869698</ArticleId></ArticleIdList></Reference><Reference><Citation>Strich JR, Tian M, Samour CS, King O, Shlobin R, et al. 2021. Fostamatinib for the treatment of hospitalized adults with COVD-19: a randomized trial. Clin. Infect. Dis 75:e491&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9890443</ArticleId><ArticleId IdType="pubmed">34467402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>